Suppr超能文献

糖原贮积病 I 型中肝细胞腺瘤形成的自然史。

Natural history of hepatocellular adenoma formation in glycogen storage disease type I.

机构信息

Glycogen Storage Disease Program and Division of Pediatric Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL 32610-0296, USA.

出版信息

J Pediatr. 2011 Sep;159(3):442-6. doi: 10.1016/j.jpeds.2011.02.031. Epub 2011 Apr 9.

Abstract

OBJECTIVE

To characterize the natural history and factors related to hepatocellular adenoma (HCA) development in glycogen storage disease type Ia (GSD Ia).

STUDY DESIGN

Retrospective chart review was performed for 117 patients with GSD Ia. Kaplan-Meier analysis of HCA progression among two groups of patients with GSD Ia (5-year mean triglyceride concentration ≤ 500 mg/dL and >500 mg/dL); analysis of serum triglyceride concentration, body mass index SDS, and height SDS between cases at time of HCA diagnosis and age- and sex-matched control subjects.

RESULTS

Logrank analysis of Kaplan-Meier survival curve demonstrated a significant difference in progression to HCA between the 5-year mean triglyceride groups (P = .008). No significant difference was detected in progression to adenoma event between sexes. Serum triglyceride concentration was significantly different at time of diagnosis of adenoma (737 ± 422 mg/dL) compared with control subjects (335 ± 195 mg/dL) (P = .009). Differences in height SDS (P = .051) and body mass index SDS (P = .066) approached significance in our case-control analysis.

CONCLUSION

Metabolic control may be related to HCA formation in patients with GSD Ia. Optimizing metabolic control remains critical, and further studies are warranted to understand the pathogenesis of adenoma development.

摘要

目的

描述糖原贮积病 Ia 型(GSD Ia)中肝细胞腺瘤(HCA)的自然史和相关因素。

研究设计

对 117 例 GSD Ia 患者进行回顾性图表审查。对 GSD Ia 两组患者(5 年平均甘油三酯浓度≤500mg/dL 和>500mg/dL)中 HCA 进展的 Kaplan-Meier 分析;在 HCA 诊断时和年龄、性别匹配的对照组中,分析病例的血清甘油三酯浓度、体重指数 SDS 和身高 SDS。

结果

Kaplan-Meier 生存曲线的对数秩分析显示,两组 5 年平均甘油三酯的 HCA 进展差异有统计学意义(P =.008)。性别之间腺瘤事件的进展无显著差异。与对照组相比,诊断为腺瘤时的血清甘油三酯浓度明显升高(737±422mg/dL 比 335±195mg/dL)(P =.009)。我们的病例对照分析中,身高 SDS(P =.051)和体重指数 SDS(P =.066)的差异有统计学意义。

结论

代谢控制可能与 GSD Ia 患者的 HCA 形成有关。优化代谢控制仍然至关重要,需要进一步研究以了解腺瘤发展的发病机制。

相似文献

1
Natural history of hepatocellular adenoma formation in glycogen storage disease type I.
J Pediatr. 2011 Sep;159(3):442-6. doi: 10.1016/j.jpeds.2011.02.031. Epub 2011 Apr 9.
2
Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease.
Mol Genet Metab. 2008 Apr;93(4):398-402. doi: 10.1016/j.ymgme.2007.10.134. Epub 2008 Feb 20.
4
Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia.
J Hepatol. 2007 Nov;47(5):658-63. doi: 10.1016/j.jhep.2007.05.012. Epub 2007 Jun 18.
6
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.
Hum Mol Genet. 2009 Dec 15;18(24):4781-90. doi: 10.1093/hmg/ddp441. Epub 2009 Sep 16.
8
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
J Hepatol. 2013 Feb;58(2):350-7. doi: 10.1016/j.jhep.2012.09.030. Epub 2012 Oct 6.
9
Successful treatment of multiple hepatocellular adenomas with percutaneous radiofrequency ablation.
World J Gastroenterol. 2013 Nov 14;19(42):7480-6. doi: 10.3748/wjg.v19.i42.7480.
10
Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
Biochem Biophys Res Commun. 2020 Jan 29;522(1):1-7. doi: 10.1016/j.bbrc.2019.11.061. Epub 2019 Nov 15.

引用本文的文献

2
Empagliflozin as treatment in glycogen storage disease type IB patients.
Mol Genet Metab Rep. 2025 May 3;43:101226. doi: 10.1016/j.ymgmr.2025.101226. eCollection 2025 Jun.
3
Diagnosing glycogen storage disease type 1b in adulthood: A case with multiple hepatocellular adenomas.
Hepatol Forum. 2024 Dec 25;6(1):26-28. doi: 10.14744/hf.2024.2024.0008. eCollection 2025.
4
Efficacy of magnetic resonance imaging in managing glycogen storage disease.
Orphanet J Rare Dis. 2025 Mar 27;20(1):144. doi: 10.1186/s13023-025-03605-7.
5
MRI features of hepatocellular adenomas in children: clinical and radiological review.
Pediatr Radiol. 2025 Mar;55(3):488-498. doi: 10.1007/s00247-025-06177-7. Epub 2025 Jan 31.
8
Integrative analysis of pathogenic variants in glucose-6-phosphatase based on an AlphaFold2 model.
PNAS Nexus. 2024 Jan 29;3(2):pgae036. doi: 10.1093/pnasnexus/pgae036. eCollection 2024 Feb.
9
Development of hepatocellular adenomas in a patient with glycogen storage disease Ia treated with growth hormone therapy.
JIMD Rep. 2023 Aug 18;64(5):303-311. doi: 10.1002/jmd2.12381. eCollection 2023 Sep.
10
Glycogen storage diseases: An update.
World J Gastroenterol. 2023 Jul 7;29(25):3932-3963. doi: 10.3748/wjg.v29.i25.3932.

本文引用的文献

1
Metabolism and proliferation share common regulatory pathways in cancer cells.
Oncogene. 2010 Aug 5;29(31):4369-77. doi: 10.1038/onc.2010.182. Epub 2010 May 31.
2
Subtype classification of hepatocellular adenoma.
Dig Surg. 2010;27(1):39-45. doi: 10.1159/000268406. Epub 2010 Apr 1.
3
Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.
Hum Mol Genet. 2009 Dec 15;18(24):4781-90. doi: 10.1093/hmg/ddp441. Epub 2009 Sep 16.
5
Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control.
J Inherit Metab Dis. 2008 Dec;31(6):729-32. doi: 10.1007/s10545-008-0919-5. Epub 2008 Aug 19.
7
Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease.
Mol Genet Metab. 2008 Apr;93(4):398-402. doi: 10.1016/j.ymgme.2007.10.134. Epub 2008 Feb 20.
8
Fatty acid synthase and cancer: new application of an old pathway.
Cancer Res. 2006 Jun 15;66(12):5977-80. doi: 10.1158/0008-5472.CAN-05-4673.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验